Диссертация (1139560), страница 46
Текст из файла (страница 46)
61,1-64.212. S. Gravas (Chair), J.N. Cornu, M.J. Drake, M. Gacci, C. Gratzke, T.R.W.Herrmann, S. Madersbacher, C. Mamoulakis, K.A.O. Tikkinen. GuidelinesAssociates: M. Karavitakis, I. Kyriazis, S. Malde, V. Sakkalis, R. Umbach.Guidelines on the Management of Non-Neurogenic Male Lower UrinaryTract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO).European Assiciation of Urology.
2018213. Schöpflin G, Rimpler H, Hänsel R. 1966. Beta sitosterol as an activeprinciple of Sabal fruit. Planta Med 14:402-407.214. Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V,Di Silverio F. Prostate growth and inflammation. J Steroid Biochem Mol Biol.2008 Feb;108(3-5):254-60.
Epub 2007 Sep 7. Review. PubMed PMID:17935971.318215. Sells H, Donovan J, Ewings P, MacDonagh RP. The development andvalidation of a quality-of-life measure to assess partner morbidity in benignprostatic enlargement. BJU Int 2000;85:440–5.216. Shapiro E., Hartanto V. and Lepor H. (1992) The response to alphablockade in benign prostatic hyperplasia is related to the percent area densityof prostate smooth muscle.
Prostate 21, 297-307.217. Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, de la Taille A,Terry S. Lipidosterolic extract of serenoa repens modulates the expression ofinflammation related-genes in benign prostatic hyperplasia epithelial andstromal cells. Int J Mol Sci. 2013 Jul 10;14(7):14301-20. doi:10.3390/ijms140714301. PubMed PMID: 23846725; PubMed CentralPMCID: PMC3742245.218.
Smith GCS, Pell JP. Parachute use to prevent death and major traumarelated to gravitational challenge: systematic review of randomised controlledtrials. BMJ: British Medical Journal. 2003;327(7429):1459-1461.219. St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Lieber MM,Jacobsen SJ. Longitudinal association between prostatitis and development ofbenign prostatic hyperplasia. Urology 2008;71:475–9.220. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ.Protective association between nonsteroidal anti-inflammatory drug use andmeasures of benign prostatic hyperplasia.
Am J Epidemiol 2006;164:760–8.221. Steiner G, Gessl A, Kramer G, et al. Phenotype and function of peripheraland prostatic lymphocytes in patients with benign prostatic hyperplasia. JUrol. 1994;151:480–484.222. Steiner GE, Djavan B, Kramer G, Handisurya A, Newman M, Lee C,Marberger M. The picture of the prostatic lymphokine network is becomingincreasingly complex.
Rev Urol. 2002 Fall;4(4):171-7. PubMed PMID:16985676; PubMed Central PMCID: PMC1475993.319223. Stratton LG, Ewing LL, Desjardin C. Efficacy of testosterone-filledpolydimethylsiloxane implants in maintaining plasma testosterone in rabbits.J Reprod Fert 1973; 35: 235.224. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S,Malbecq W, Malice MP. 1994. Comparison of finasteride (Proscar®) andSerenoa repens (Permixon®) in the inhibition of 5-α reductase in healthy malevolunteers. Eur Urol 26:247-252.225. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ.
Serenoa repens forbenignprostatichyperplasia. CochraneDatabaseofSystematicReviews 2012, Issue 12. Art. No.: CD001423226. Tammela T., Kontturi M., Lukkarinen O. Postoperative urinary retention.I. Incidence and predisposing factors. Scand. J. Urol. Nephrol.,1986;20(3):197-201.227. The mainstreaming of alternative medicine. Consum Rep. 2000May;65(5):17-25. PubMed PMID: 11010636.228. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M,Zechner O, Steiner GE.
Phenotypic characterization of infiltrating leukocytesin benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107.229. Timmermans L. M. and Timmermans L. G. (1990) Mesure de l’activitedes extraits d’Echinaceae et the'Sabal dans le traitement des megavessiesidiopa- thiques chez la femme. Acta Urol. Belg. 58, 43-59230. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinarytract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’,and their effect on quality of life in a community-based survey of men in theUK.
BJU Int 1999;83:410–5.231. Tsang K. K. and Garraway W. M. (1993) Impact of benign prostatichyperplasia on general well-being of men. Prostate 23, 1-17.232. Tzeng SH, Ko WC, Ko FN, Teng CM. 1991. Inhibition of plateletaggregation by some flavonoids. Thromb Res 64:91-100.320233. United States Dispensatory - 1918 - Botanicals Only - F - Page 44 TheSouthwest School of Botanical Medicine234. Vallancien G, Emberton M, Alcaraz A, et al.
Alfuzosin 10 mg once dailyfor treating benign prostatic hyperplasia: a 3-year experience in real-lifepractice. BJU Int 2008; 101:847–52.235. Vallancien G, Pariente P. 2001. Treatment of lower urinary tract symptomssuggestive of benign prostatic obstruction in real life practice in France.Prostate Cancer and Prostatic Diseases 4:124-131.236.
Vela Navarrete R, Garcia Cardoso J, Barat A, Manzarbeitia F, Lopez FarreA. Effects of the lipido-sterolic extract of Serenoa repens (Permixon) oninfiltrating cells and inflammatory markers in prostatic tissues from BPHpatients. Eur Urol 2002;1:62.237. Vibhash C. Mishra, John Browne, and Mark Emberton. Role of prostatemassage – systematic review. Urology 72 (4), 2008238. VinarovAZ. Long-term treatment of BPH symptoms with Serenoa Repens.European Urology Today. Vol. 23 No.2 - April/May 2011. P.9.239.
Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brähler E,Weidner W. A pollen extract (Cernilton) in patients with inflammatorychronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised,prospective, double-blind, placebo-controlled phase 3 study. Eur Urol.
2009Sep;56(3):544-51. doi: 10.1016/j.eururo.2009.05.046. Epub 2009 Jun 3.240. Wagner H, Flachsbarth H. 1981. A new antiphlogistic principle from Sabalserrulata, I. Planta Med 41:244-251.241. Wagner H, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, StuppnerH, Jurcic K, Le Turdu M, Fang JN. 1985. Immunostimulating action ofpolysaccharides (heteroglycans) from higher plants. Arzneimittelforschung35:1069-1075.242. Wagner VH, Proksch A, Riess-Maurer I, Vollmar A, Odenthal S, StuppnerH, Jurcic K, Le Turdu M, Heur YH.
1984. Immunostimulating action of321polysaccharides (heteroglycans) from higher plants. Arzneimittelforschung34:659-661.243. Walsh Р. С., Retik А. В., Vaughan E. D., Wein A. J. Campbell’s urology,11th edition, 2016 volume 1, p.990.244. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. 1994. Lignans andflavonoids inhibit aromatase enzyme in human preadipocytes. J SteroidBiochem Mol Biol 50:205-212.245. Wehrberger C, Dreikorn K, Schmitz-Dräger BJ, Oelke M, MadersbacherS. Phytotherapy of benign prostate syndrome and prostate cancer: better thanplacebo.
Urologe A. 2012 Dec;51(12):1674-82.246. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project:benign prostatic hyperplasia. J Urol. 2008 May;179(5 Suppl):S75-80. doi:10.1016/j.juro.2008.03.141.247. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinarytract symptom severity: results from the Health Professionals Follow-UpStudy. Urology 2002;59: 245–50.248. Wilt T, Ishani A, Stark G, MacDonald R, Mulrow C, Lau J.
Serenoa repensforbenignprostatichyperplasia.CochraneDatabaseSystRev.2000;(2):CD001423. Review249. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmettoextracts for treatment of benign prostatic hyperplasia: a systematic review.JAMA. 1998 Nov 11;280(18):1604-9.250. Zwijsen R. M. L., Oudenhoven I. M. J. and de Haan L. H. J. Effects ofcholesterol and oxysterol on gap junctional communication between humansmooth muscle cells. 1992.
Eur. J. Pharmac. 228, 115-120..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
